Adial Pharmaceuticals, Inc. acquisition of Azora Therapeutics, Inc.

Adial Pharmaceuticals, Inc. completed its acquisition of Azora Therapeutics, Inc. on 2026-06-11, according to the Form 8-K Adial Pharmaceuticals, Inc. filed with the SEC on 2026-06-11. The filing states a price of $26.8 million.

Want the whole picture on Adial Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Adial Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Adial Pharmaceuticals, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

What the filing says

On June 11, 2026, the Company completed its acquisition of Azora.

The price, in the filing's words

The Financing On June 11, 2026, in connection with and as a condition to closing of the Merger, the Company entered into a Securities Purchase Agreement (the " Purchase Agreement ") with the purchasers named therein (the " PIPE Investors "), pursuant to which the Company agreed to issue and sell to the PIPE Investors, in a private placement transaction, (i) at the initial closing (the " Initial Closing ") Initial Closing Pre-Funded Warrants to purchase an aggregate of 9,749,345 shares of Common Stock, at a price of $2.7489 per Initial Closing Pre-Funded Warrant (the " Purchase Price "), for an aggregate purchase price of $26.8 million; and (ii) at one or more subsequent closings (each, a " M

More from the filing

- Completion of Acquisition or Disposition of Assets.

Agreement and Plan of Merger On June 11, 2026, Adial Pharmaceuticals, Inc., a Delaware corporation (the " Company " or " Adial "), acquired Azora Therapeutics, Inc., a Delaware corporation (" Azora "), in accordance with the terms of the Agreement and Plan of Merger, dated June 11, 2026 (the " Merger Agreement "), by and among the Company, Adial Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (" First Merger Sub "), Adial Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (" Second Merger Sub "), and Azo

Pursuant to the Merger Agreement, First Merger Sub merged with and into Azora, pursuant to which Azora was the surviving corporation and became a wholly owned subsidiary of the Company (the " First Merger " and the effective time of the First Merger, the " First Effective Time ").

Quoted from Adial Pharmaceuticals, Inc.'s Form 8-K.

This is the only completed acquisition Adial Pharmaceuticals, Inc. reported under Item 2.01 in the last twelve months.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.

Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.

All recent acquisitions